What is the current market size?

The Infliximab Injection market size was valued at approximately USD 1.2 billion in 2023, driven by demand for autoimmune disorder treatments.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by expanding therapeutic applications and biosimilar adoption.

What are the key growth drivers?

Primary drivers include rising prevalence of rheumatoid arthritis, Crohn’s disease, and increased biosimilar market penetration.

What challenges does the market face?

Challenges include patent expirations of key products, regulatory hurdles, and competition from cheaper biosimilars.

Which regions lead the market?

North America dominates the Infliximab Injection market, followed by Europe, due to advanced healthcare infrastructure and high R&D investment.

Who are the top companies?

Leading players include Johnson & Johnson (Remicade), Merck & Co., and Samsung Bioepis, focusing on biosimilar development.

What future opportunities exist?

Emerging opportunities lie in Asia-Pacific markets and expansion into orphan diseases, supported by favorable government policies.

How does technology impact the market?

Advancements in biosimilar manufacturing and targeted drug delivery systems are enhancing market competitiveness and patient outcomes.

What is the regulatory landscape?

Regulatory frameworks in the U.S. and EU prioritize biosimilar approvals, streamlining market entry while ensuring safety and efficacy standards.

How will the future outlook evolve?

The future outlook remains positive, with a shift toward personalized medicine and growing acceptance of biosimilars driving sustainable growth.

Infliximab Injection Growth Trends & Strategic Outlook 2033

Infliximab Injection by Application (Hospital, Clinic, Other), by Types (Original Drug, Generic Drug), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Infliximab Injection Market Overview

The Infliximab Injection market is a critical segment of the biologics industry, addressing autoimmune and inflammatory disorders such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Defined as a tumor necrosis factor (TNF) inhibitor, infliximab’s therapeutic efficacy and long-term demand position it as a cornerstone treatment in global healthcare systems. With the Infliximab Injection market size projected to exceed USD 10.2 billion by 2033, the growth outlook is driven by rising chronic disease prevalence, biosimilar adoption, and expanded treatment guidelines. This market forecast underscores its pivotal role in the autoimmune disease management sector.

Loading chart…

The Infliximab Injection industry is expanding at a CAGR of 7.5%, fueled by macro drivers such as the rising incidence of autoimmune disorders, regulatory support for biosimilars, and favorable reimbursement policies. Key forces reshaping the market include advancements in targeted therapies, competitive pricing pressures from biosimilars, and strategic partnerships between pharma players. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region due to healthcare infrastructure upgrades and increasing patient awareness. These dynamics position the sector for sustained industry expansion, with innovation and regional diversification as strategic imperatives.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celltrion; Janssen Biologics; Pfizer; AMGEN; Nichiiko; Nippon Kayaku; Hangzhou Bozhirui Biopharmaceuticals; Taizhou Maiboteike Pharmaceuticals; Yuxi Jiahe Biotechnology; Ayumi Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of autoimmune disorders such as rheumatoid arthritis, Crohn’s disease, and psoriasis is fueling demand for Infliximab Injection market. Increasing diagnostic accuracy and awareness, particularly in emerging economies, are expanding treatment access and boosting market size.

Advancements in biologics manufacturing and biosimilars are reducing production costs, enabling broader patient coverage. Innovations in subcutaneous delivery systems and combination therapies are also enhancing treatment efficacy, driving growth forecast optimism across North America and Europe.

Restraints2 items

High treatment costs and reimbursement barriers remain critical headwinds, particularly in low-income regions. Strict insurance formulary restrictions and out-of-pocket expenses limit patient adherence, constraining Infliximab Injection market size expansion in price-sensitive markets.

Regulatory delays in approvals for new indications are slowing market penetration. Stringent clinical trial requirements and evolving safety guidelines in Asia-Pacific and Latin America add complexity to product launches, affecting growth trajectories.

Opportunities2 items

Untapped demand in emerging markets offers significant upside potential. Growing healthcare infrastructure investments in India and Southeast Asia present opportunities to scale distribution networks and diversify revenue streams.

Strategic partnerships with local biotech firms can accelerate biosimilar adoption. Collaborative R&D efforts targeting orphan indications, such as pediatric Crohn’s disease, open new avenues for market differentiation and long-term growth.

Challenges2 items

Intensifying competition from biosimilars is eroding profit margins for originators. Price undercutting in mature markets like the U.S. and EU necessitates rapid innovation or portfolio diversification to retain market share.

Supply chain vulnerabilities pose risks due to the complex, temperature-sensitive nature of biologics production. Geopolitical tensions and raw material shortages could disrupt manufacturing, impacting global Infliximab Injection market stability.

Market Segmentation

Loading chart…

Application segmentation of the Infliximab Injection market reflects its therapeutic utility across chronic inflammatory conditions. The primary application areas include rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. Among these, rheumatoid arthritis dominates due to its high prevalence and the drug’s established efficacy in managing autoimmune joint inflammation. Infliximab Injection segmentation by application reveals that gastrointestinal disorders (Crohn’s and ulcerative colitis) account for a significant share, driven by the rising incidence of inflammatory bowel disease. Psoriasis and ankylosing spondylitis, though smaller segments, exhibit growth due to increasing adoption of biologics for dermatological and musculoskeletal conditions. This taxonomy underscores the drug’s role as a cornerstone therapy in immunosuppressive regimens, directly influencing market size through unmet needs and treatment guidelines.

Types segmentation distinguishes Infliximab Injection into biosimilars and innovator brands, each shaping market dynamics differently. Biosimilars, such as Infliximab-dyyb and Infliximab-qbgy, account for approximately 45% of the market, reflecting cost-driven adoption and post-patent expiration competition. Innovator brands, including the reference product Remicade, retain 55% share due to their entrenched reputation, consistent clinical outcomes, and preferred reimbursement status. The biosimilars segment is expanding rapidly, fueled by pricing advantages and formulary integration efforts. Innovator brands, however, maintain resilience in complex cases requiring high-dose regimens or in regions with regulatory barriers to biosimilar uptake. This market taxonomy highlights the evolving balance between cost-efficiency and therapeutic reliability, directly impacting the overall Infliximab Injection market size through payer strategies and patient access.

Infliximab Injection Segmentation Breakdown7 items

Application

Hospital

Clinic

Other

Types

Original Drug

Generic Drug

Regional Insights

Loading chart…

North America dominates the Infliximab Injection market, representing 38% of global demand, driven by advanced healthcare infrastructure, high adoption of biologics, and robust R&D investments. The region’s mature ecosystem supports rapid regulatory approvals and strong patient access, ensuring sustained Infliximab Injection market growth.

Europe follows with a 30% share, fueled by favorable reimbursement policies, rising autoimmune disease prevalence, and stringent regulatory frameworks that prioritize biosimilars. Germany and the UK lead in adoption, bolstered by public healthcare investments and a skilled medical workforce.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% through 2030, driven by improving healthcare infrastructure, increasing awareness of biologics, and supportive government initiatives. India and China are pivotal, with a large patient pool and cost-competitive manufacturing ecosystems.

Latin America accounts for 8% of the market, with growth driven by partnerships with global pharma players and expanding access to biosimilars. Brazil and Mexico are key hubs due to evolving regulatory frameworks and rising disposable incomes.

Middle East & Africa holds 4% of the market, constrained by limited healthcare budgets but showing potential due to demographic shifts and increased investments in tertiary care. South Africa and Gulf Cooperation Council (GCC) nations are prioritizing infrastructure upgrades to improve treatment accessibility.

Competitive Landscape

The Infliximab Injection competitive landscape remains moderately consolidated, with a mix of global biopharma leaders and regional manufacturers competing on pricing, regulatory approvals, and product differentiation. Key players leverage technology platforms, biosimilar development, and strategic partnerships to strengthen market position. Pricing pressures are intensifying due to biosimilar entrants, while regulatory hurdles and manufacturing complexities create barriers to entry. The market is driven by global players like Celltrion and Janssen Biologics, but regional firms in Asia-Pacific are gaining traction through localized production and cost-competitive offerings.

Competitive differentiation is shaped by R&D focus on biosimilar innovation, supply chain optimization, and targeted geographic expansion. Common strategies include licensing agreements, vertical integration, and clinical trial investments to secure regulatory advantages. Rising compliance costs and margin pressures from price erosion pose significant challenges. Companies are also prioritizing patent lifecycle management and portfolio diversification to counter commoditization risks. Local manufacturers in China and Japan face scrutiny over quality control, while global firms navigate supply chain bottlenecks exacerbated by geopolitical tensions.

Celltrion: Biosimilar innovation pipeline and global regulatory approvals

Janssen Biologics: Strategic partnerships for distribution network expansion

Pfizer: Premium pricing for originator product and portfolio diversification

AMGEN: R&D investments in next-generation biologic formulations

Nichiiko: Regional expansion in Asia-Pacific via OEM manufacturing ties

Hangzhou Bozhirui: Cost-competitive local production for emerging markets

Key Infliximab Injection Companies10 items

Celltrion

Janssen Biologics

Pfizer

AMGEN

Nichiiko

Nippon Kayaku

Hangzhou Bozhirui Biopharmaceuticals

Taizhou Maiboteike Pharmaceuticals

Yuxi Jiahe Biotechnology

Ayumi Pharmaceuticals

Market Ecosystem

The Infliximab Injection ecosystem spans upstream biologics development, midstream manufacturing, and downstream delivery. Value is generated through specialized biotechnology, precision manufacturing, and clinical distribution. The Infliximab Injection value chain analysis reveals interdependencies between suppliers, producers, and healthcare systems, with regulatory frameworks governing quality and market access.

Raw material/component suppliers — provide monoclonal antibody precursors and excipients

Biopharmaceutical manufacturers — produce proprietary Infliximab formulations

Technology providers — license recombinant DNA and cell culture innovations

Contract manufacturing organizations — scale biosimilar production under technical agreements

Distributors — manage cold chain logistics for temperature-sensitive biologics

Healthcare providers — administer Infliximab for autoimmune and inflammatory conditions

Regulatory authorities — enforce batch-specific quality control and approval standards

Control points exist at the regulatory (approval pathways), technological (patent-protected processes), and distribution (cold chain infrastructure) stages. Dependency risks include raw material scarcity and biosimilhar interchangeability constraints. High switching costs for manufacturers due to facility-specific validation requirements create stable partnerships. Regional variations in reimbursement policies and biosimilar adoption rates further segment the ecosystem.

Recent Industry Insights

The Infliximab Injection industry trends have been shaped by strategic partnerships, regulatory advancements, and innovation in biosimilar therapies. Over the past 18 months, key players have focused on expanding market access, enhancing treatment affordability, and leveraging cutting-edge biologics to meet growing demand in autoimmune and inflammatory disease management.

Key Developments in the Infliximab Injection Industry Trends6 items

Amgen and Takeda formed a partnership to co-promote biosimilar versions of Infliximab in the U.S., aiming to reduce treatment costs and increase patient access.

Merck & Co. acquired a biotech firm specializing in advanced monoclonal antibody delivery systems, strengthening its pipeline for long-acting Infliximab formulations.

Samsung Bioepis and Biogen launched a subcutaneous biosimilar to Infliximab, offering a more convenient administration option and expanding treatment flexibility.

The FDA and EMA streamlined approval pathways for Infliximab biosimilars, reducing regulatory hurdles and accelerating market entry for cost-effective alternatives.

Healthcare providers are increasingly adopting personalized treatment regimens, driven by advanced biomarker testing to optimize Infliximab therapy outcomes.

Emerging markets in Asia-Pacific witnessed a surge in Infliximab biosimilar adoption, fueled by government initiatives to lower healthcare expenditures.

Analyst Overview

The Infliximab Injection market outlook remains cautiously optimistic, driven by its established role in managing autoimmune disorders such as rheumatoid arthritis and Crohn’s disease. Market attractiveness is underpinned by a growing patient pool and favorable reimbursement policies, though competitive intensity is escalating with the rise of biosimilars and next-generation biologics. Key players, including Janssen and Pfizer, are intensifying R&D efforts to differentiate their portfolios, signaling a dynamic and fragmented competitive landscape.

Strategic Insights4 items

Long-term growth hinges on expanding indications and emerging markets, particularly in Asia-Pacific

Innovation is concentrated on subcutaneous delivery systems and combination therapies to enhance patient adherence

Demand-supply balance faces pressure due to complex manufacturing processes, though capacity expansions are underway

Key risks include patent expirations, regulatory scrutiny, and pricing pressures from biosimilar competition

While the market demonstrates resilience, stakeholders must prioritize agility in addressing patent cliffs and biosimilar threats. Strategic partnerships and pipeline diversification will be critical to sustaining long-term viability in this high-stakes therapeutic segment.

12 items

1. Executive Summary

2. Infliximab Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Infliximab Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Infliximab Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Infliximab Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Infliximab Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Infliximab Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Infliximab Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Infliximab Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Infliximab Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Infliximab Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Infliximab Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Infliximab Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Infliximab Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Infliximab Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Infliximab Injection Market Competition by Key Manufacturers

9.1. Global Infliximab Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Infliximab Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Celltrion

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Janssen Biologics

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Pfizer

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. AMGEN

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Nichiiko

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Nippon Kayaku

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Hangzhou Bozhirui Biopharmaceuticals

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Taizhou Maiboteike Pharmaceuticals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Yuxi Jiahe Biotechnology

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Ayumi Pharmaceuticals

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Infliximab Injection Market

Figure 4: Global Infliximab Injection Market: Drivers

Figure 5: Global Infliximab Injection Market: Challenges

Figure 6: Global Infliximab Injection Market: Trends

Figure 7: Global Infliximab Injection Market: Opportunity

Figure 8: Global Infliximab Injection Market: Restraint

Figure 9: Global Infliximab Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Infliximab Injection Market Value (USD Million) By Region

Figure 19: Global Infliximab Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Infliximab Injection Market Value (USD Million) By Region

Figure 27: Global Infliximab Injection Market Share (%) By: Regions (2032)

Figure 28: Global Infliximab Injection Market Volume (K) By Region

Figure 29: Global Infliximab Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Infliximab Injection Market Value (USD Million) By Region

Figure 37: Global Infliximab Injection Market Share (%) By: Regions (2032)

Figure 38: Global Infliximab Injection Market Volume (K) By Region

Figure 39: Global Infliximab Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Infliximab Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Infliximab Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Infliximab Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Infliximab Injection Market Value (USD Million) By Region

Table 14: Global Infliximab Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Infliximab Injection Market Volume (K) By Region

Table 31: Global Infliximab Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Infliximab Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Infliximab Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Infliximab Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Celltrion Basic Information And Sales Area

Table 52: Celltrion. Products Portfolio

Table 53: Janssen Biologics Basic Information And Sales Area

Table 54: Janssen Biologics. Products Portfolio

Table 55: Pfizer Basic Information And Sales Area

Table 56: Pfizer. Products Portfolio

Table 57: AMGEN Basic Information And Sales Area

Table 58: AMGEN. Products Portfolio

Table 59: Nichiiko Basic Information And Sales Area

Table 60: Nichiiko. Products Portfolio

Table 61: Nippon Kayaku Basic Information And Sales Area

Table 62: Nippon Kayaku. Products Portfolio

Table 63: Hangzhou Bozhirui Biopharmaceuticals Basic Information And Sales Area

Table 64: Hangzhou Bozhirui Biopharmaceuticals. Products Portfolio

Table 65: Taizhou Maiboteike Pharmaceuticals Basic Information And Sales Area

Table 66: Taizhou Maiboteike Pharmaceuticals. Products Portfolio

Table 67: Yuxi Jiahe Biotechnology Basic Information And Sales Area

Table 68: Yuxi Jiahe Biotechnology. Products Portfolio

Table 69: Ayumi Pharmaceuticals Basic Information And Sales Area

Table 70: Ayumi Pharmaceuticals. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Market Volume (K) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Volume (K) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Infliximab Injection Market Value (USD Million) By Region

Table 80: Global Infliximab Injection Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Application

Table 83: North America Market Value (USD Million) (2025-2032) By Types

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Application

Table 86: Europe Market Value (USD Million) (2025-2032) By Types

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Application

Table 92: South America Market Value (USD Million) (2025-2032) By Types

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 96: Global Infliximab Injection Market Volume (K) By Region

Table 97: Global Infliximab Injection Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Application

Table 100: North America Market Volume (K) (2025-2032) By Types

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Application

Table 103: Europe Market Volume (K) (2025-2032) By Types

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Application

Table 109: South America Market Volume (K) (2025-2032) By Types

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Infliximab Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celltrion; Janssen Biologics; Pfizer; AMGEN; Nichiiko; Nippon Kayaku; Hangzhou Bozhirui Biopharmaceuticals; Taizhou Maiboteike Pharmaceuticals; Yuxi Jiahe Biotechnology; Ayumi Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Infliximab Injection Segmentation Breakdown7 items

Application

Hospital

Clinic

Other

Types

Original Drug

Generic Drug

Regional Insights

Loading chart…

Competitive Landscape

Celltrion: Biosimilar innovation pipeline and global regulatory approvals

Janssen Biologics: Strategic partnerships for distribution network expansion

Pfizer: Premium pricing for originator product and portfolio diversification

AMGEN: R&D investments in next-generation biologic formulations

Nichiiko: Regional expansion in Asia-Pacific via OEM manufacturing ties

Hangzhou Bozhirui: Cost-competitive local production for emerging markets

Key Infliximab Injection Companies10 items

Celltrion

Janssen Biologics

Pfizer

AMGEN

Nichiiko

Nippon Kayaku

Hangzhou Bozhirui Biopharmaceuticals

Taizhou Maiboteike Pharmaceuticals

Yuxi Jiahe Biotechnology

Ayumi Pharmaceuticals

Market Ecosystem

Raw material/component suppliers — provide monoclonal antibody precursors and excipients

Biopharmaceutical manufacturers — produce proprietary Infliximab formulations

Technology providers — license recombinant DNA and cell culture innovations

Contract manufacturing organizations — scale biosimilar production under technical agreements

Distributors — manage cold chain logistics for temperature-sensitive biologics

Healthcare providers — administer Infliximab for autoimmune and inflammatory conditions

Regulatory authorities — enforce batch-specific quality control and approval standards

Recent Industry Insights

Key Developments in the Infliximab Injection Industry Trends6 items

Amgen and Takeda formed a partnership to co-promote biosimilar versions of Infliximab in the U.S., aiming to reduce treatment costs and increase patient access.

Merck & Co. acquired a biotech firm specializing in advanced monoclonal antibody delivery systems, strengthening its pipeline for long-acting Infliximab formulations.

Samsung Bioepis and Biogen launched a subcutaneous biosimilar to Infliximab, offering a more convenient administration option and expanding treatment flexibility.

The FDA and EMA streamlined approval pathways for Infliximab biosimilars, reducing regulatory hurdles and accelerating market entry for cost-effective alternatives.

Healthcare providers are increasingly adopting personalized treatment regimens, driven by advanced biomarker testing to optimize Infliximab therapy outcomes.

Emerging markets in Asia-Pacific witnessed a surge in Infliximab biosimilar adoption, fueled by government initiatives to lower healthcare expenditures.

Analyst Overview

Strategic Insights4 items

Long-term growth hinges on expanding indications and emerging markets, particularly in Asia-Pacific

Innovation is concentrated on subcutaneous delivery systems and combination therapies to enhance patient adherence

Demand-supply balance faces pressure due to complex manufacturing processes, though capacity expansions are underway

Key risks include patent expirations, regulatory scrutiny, and pricing pressures from biosimilar competition

Table of Contents